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Abstract
Background: In drug development, it is important to have an understanding of the full spectrum of co-morbidities
to be expected in the group of patients with the disease of interest. It is usually a challenge to identify the less
common events associated with the target disease, even if these events are severe. The purpose of this study is to
identify co-morbidities associated with rheumatoid arthritis (RA) as compared with a control group, using a large
health care database.
Methods: Marketscan US claims database was used for this retrospective cohort study. Selected were records of
persons aged at least 16 Y with at least two claims for RA, and with active insurance status on June 30,2007. The
control group had at least two claims for eczema/dermatitis.
Controls were matched by age, gender and insurance status (Medicare or not). All co-morbidities with an ICD9
diagnostic code were identified in the RA and control groups, during a one-year window. Relative risks (RRs) were
calculated. Diagnoses were rank-ordered by magnitude of RR. Codes covering RA and arthropathy were excluded.
In order to get stable estimates, rank-ordering was performed for diagnoses occurring in at least 20 persons in the
control group.
Results: Records were selected of 62,681 persons with RA (mean age was 59.0 Y, with 73.8% female, Medicare-
covered 35%). A total of 6897 different ICD9 diagnostic codes were recorded, with 2220 codes in at least 20
persons of the control group [listed with Relative Risk]. Apart from joint/bone related conditions, strong
associations with RA (RR > 3) were found for Adverse effect medicinal and biological substance not elsewhere
classified, Unspecified adverse effect drug properly administered, Idiopathic fibrosing alveolitis, Osteomyelitis,
Immune deficiency, Elevated sedimentation rate, Tuberculin test reaction abnormal or positive, Anemia and
Cushing syndrome.
Conclusions: Data on a large number (> 60,000) of patients with a diagnosis of RA were used to analyze and to
list a large number (>2,000) of co-morbidities. Rank-ordering of RRs of diagnostic codes is a tool to identify quickly
many conditions associated with RA.
Background
In post-marketing surveillance, often questions arise
about characteristics of the patient group for which a
drug is indicated, such as the age distribution and co-
morbidities to be expected [1,2]. Therapeutic risk man-
agement involves an understanding of characteristics
specific to a group of patients for whom a drug will be
prescribed. Often, some safety issues of a new product
are predictable; however after market introduction in
practice often adverse events are reported that were not
foreseen [3,4]. A description of all co-morbidities seen
in the target population would help better understand
the patient population and thus, provide some context
for new safety issues.
Referring to Risk Management Plans (RMPs) sub-
mitted to regulatory authorities, a guide on pharmacov-
igilance published by the Medicines and Healthcare
products Regulatory Agency in the UK comments that
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rather than identifying the areas in which information is
lacking [5]. It was also noted that the relevance of the
epidemiology of the disease to the target indication is
often not sufficiently considered.
To help address these issues, data on large groups
from the general population are needed. Increasingly in
the past years, health-care databases have become avail-
able that enable the study of large numbers of patients
with follow-up data. The US Food and Drug Adminis-
tration Amendment Act of 2007 (FDAAA) called for the
establishment, under the auspices of an independent
foundation, of a set of databases of health insurance
claims data for 100 million people by 2012 [6,7]. Thus,
data on sufficient numbers of patients are becoming
more available to better understand the co-morbidities
in groups or subgroups of patients with a target disease.
Listing co-morbidities, rank-ordered by prevalence,
will show various conditions associated with the disease
of interest; these associations may be either known, or
not yet established. Additionally, such data on a patient
group will reflect the target group for a product. The
target indication is often restricted by criteria relating to
severity of disease or by treatments given earlier. While
healthcare databases usually do not have sufficient data
on stage or severity of a specific disease, prescribed
medication is usually well covered. A subgroup within a
healthcare database can be selected, identified by disease
codes and restricted by criteria on medication. Informa-
tion gathered on age/sex profile, co-morbidities and co-
medication of such a group should help to describe dis-
ease epidemiology specific for a target indication.
Rheumatoid arthritis is a chronic condition character-
ized by inflammation and modulation of immunity,
affecting many organs apart from the loco-motor sys-
tem. Various studies have described associations of RA
with selected morbidities such as infectious conditions
[8-10] and cardiovascular disease [11-14]. Because of
this potential association with many conditions, it was
chosen as the target condition to describe unselected
co-morbidity in a data-driven way. The objective was to
quantify a large number of co-morbidities associated
with RA, as compared to a control group. Associations
f o u n ds h o u l dn o tb ea s s u m e dt ob ec a u s a l ;h o w e v e r
they can provide a base for further analyses and for
hypothesis testing in different data sets.
Methods
Thomson’s MarketScan Commercial Claims and
Encounters Research Database and the Medicare Sup-
plemental from January 1, 1999 through June 30, 2007
was the data source for this analysis. Marketscan is
composed of claims submitted to health plans which
have contracts with large private employers or with
public organizations in the United States. The longitudi-
nal database covers, at the patient level, all inpatient,
outpatient, and prescription claims, as long as employees
stay enrolled. It consists of employer- and health plan
sourced data. Nearly 18 million individuals are included
in the 2006 database: employees, their spouses, and
dependents. Healthcare for these individuals is provided
under a variety of fee-for-service, fully capitated (i.e. set
amount per person), and partially capitated health plans.
Medical claims are linked to outpatient prescription
drug claims and person-level enrollment information.
This is one of the largest collections of patient data in
the US with over four billion patient records. It includes
77 contributing employers and 12 contributing health
plans, with 126 unique carriers, and Medicaid data from
eight states [15]; Medicaid covers individuals and
families with low income and resources. Elderly are well
represented, through the inclusion of groups covered by
Medicare, the US social insurance program for people
who are aged 65 years and over.
MarketScan research databases meet or exceed
requirements of the US Health Insurance Portability and
Accountability Act (HIPAA) of 1996. The MarketScan
databases underwent a statistical analysis by a third
party confirming that HIPAA requirements for fully de-
identified data sets were met. Thus, data use met
HIPAA criteria for anonymous and aggregate research
analysis and reporting of data derived from clinical
records not requiring specific patient consent or ethical
approval.
Cases were defined as persons with at least two claims
for RA [codes ICD 9: 714.0*, 714.1*, 714.2*, and 714.3*.]
that were non-diagnostic (i.e. not blood, lab, radiological
claims) with active insurance status on June 30, 2007.
At least one diagnosis of RA had to be before July 1
2006 and the index date was defined as the earliest
claim containing the diagnosis. The control group was
patients who had at least two claims for eczema/derma-
titis [codes ICD 9: 690.*, 691.*,692.*] with the same cri-
teria as the cases for insurance status and timing of the
claims. Controls were matched 1:1 to the cases, by age,
gender and health plan [Medicare or not] using propen-
sity scores.
Propensity matching was done using a logistic regres-
sion model on dependent variable RA = 0,1 where 1 =
in RA cohort and with explanatory variables: age, sex,
and health plan (Medicare or not). The propensity score
is the probability of being in the RA cohort. Then, one
control was selected for each case based on a best
match algorithm, using 8 digits of the probability value,
then 7 digits, etc. [16] Each control was used only once.
SAS version 8.2 was used for all analyses.
All co-morbidities with a level 5 - i.e. the most
detailed - ICD9 (diagnostic)c o d ew e r ei d e n t i f i e di nt h e
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Page 2 of 7case and control groups in the one-year window from
July 1, 2006 through June 30, 2007. A one-year period
prevalence was calculated for each co-morbidity for
both case and control groups. Occurrence of each co-
morbidity was counted only once for each patient.
Also, a set of relative risks (RR) was calculated for
patients aged at least 16 years old as of RA index date,
by dividing the one-year period prevalence of each co-
morbidity in the RA group with the corresponding pre-
valence in the controls. Thus, the RR represents here a
ratio of one-year prevalences. After this, the various co-
morbidities were rank-ordered by magnitude of RR; 95%
confidence intervals were added.
ICD9 codes covering arthropathies and related disor-
ders [710-719], dorsopathies [720-724] and rheumatism,
excluding the back [725-729] were excluded from the
analysis (as likely related/part RA), also mechanical
complications of internal orthopedic device, implant and
graft [996.4]. In order to obtain stable estimates, rank-
ordering was done for non-rare diagnoses (occurring in
at least 20 persons in control group).
Results
Records for 62,681 persons with RA were selected (all
ages). Mean age was 59.0 Y, with 73.8% female, 35%
Medicare-covered. A total of 6,897 different ICD9 diag-
nostic codes were recorded in this group, of which
2,220 occurred in 20 or more persons with RA.
The most prevalent co-morbidities in the cohort with
RA are listed in Table 1. At the more detailed level of
the ICD9 classification (level 5), the most commonly
registered co-morbidities were hypertension not other-
wise specified (NOS) (20.4%), benign hypertension
(19.9%), chest pain NOS (13.9%), and hyperlipidemia
not elsewhere classified (NEC)/NOS (13.9%).
A total of 61,591 persons with RA were aged at least
16 years and subsequently matched with the control
group. Demographic distribution for RA cases is shown
in Figure 1. The demographic distribution of the con-
trols was identical. Co-morbidities strongly associated
with RA in the case group compared to controls are
shown in Table 2 and Figure 2. A full set of co-morbid-
ities is provided in additional File 1: Rank-ordered rela-
t i v er i s k so fc o - m o r b i d i t i e si np a t i e n t sw i t hr h e u m a t o i d
arthritis.
Additional file 2 shows top 30 of relative risks as well
as odds ratios of co-morbidities in patients with RA;
comparator group had dermatitis/eczema diagnosis
Additional file 3 shows same analysis as additional file
2, however with a different (random) comparator group.
Strong associations with RA (RR > 3) were found
for psoriatic arthropathy, adverse effect to medicine/bio-
logical, reaction to internal joint prosthesis, unspecified
adverse effect, osteoporosis, idiopathic fibrosing
Table 1 Most common co-morbidities in cohort with
rheumatoid arthritis (N = 62,681, all ages)*
Condition (ICD-9 code) Number of
persons
Percent
4019 Hypertension NOS 12,773 20.4%
4011 Benign hypertension 12,482 19.9%
78650 Chest pain NOS 8,742 13.9%
2724 Hyperlipidemia NEC/NOS 8,690 13.9%
25000 Diabetes Mellitus II without
complication
7,504 12.0%
78079 Malaise & fatigue NEC 6,046 9.6%
5990 Urinary tract infection NOS 5,965 9.5%
78900 Abdominal pain unspecified site 5,712 9.1%
7862 Cough 5,649 9.0%
2449 Hypothyroidism NOS 5,524 8.8%
78605 Shortness of breath 5,516 8.8%
4660 Acute bronchitis 5,400 8.6%
2720 Pure hypercholesterolemia 5,046 8.1%
4619 Acute sinusitis NOS 4,833 7.7%
2859 Anemia NOS 4,632 7.4%
73300 Osteoporosis NOS 4,529 7.2%
41401 Coronary atherosclerosis native
vessel
4,325 6.9%
53081 Esophageal reflux 4,288 6.8%
7020 Actinic keratosis 4,249 6.8%
73390 Bone & cartilage disease NOS 4,113 6.6%
4659 Acute upper respiratory infection
NOS
4,112 6.6%
496 Chronic airway obstruct NEC 4,041 6.4%
36616 Senile nuclear cataract 3,914 6.2%
78609 Respiratory abnormality NEC 3,605 5.8%
7840 Headache 3,246 5.2%
41400 Coronary atherosclerosis unspec.
vessel
3,002 4.8%
*Excluded arthritis/RA-related codes ICD 710-729; 996.4.
NOS: Not otherwise specified NEC: Not elsewhere classified.
Figure 1 Age/sex distribution of rheumatoid arthritis cases 16
years and older (N = 61,591).
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sedimentation rate, tuberculin test reaction, anemia and
C u s h i n gs y n d r o m e[ T a b l e2 ,F i g u r e2 ] .A sd e s c r i b e di n
the Methods section, a set of ICD codes covering condi-
tions of the loco-motor system was excluded from the
analysis. All RRs in Table 2 were statistically significant.
The full set of co-morbidities as shown in additional
File 1 includes many with a RR < 1, i.e. associated with
the control group. Many of these are skin conditions.
Discussion
Data on a large number of patients (>60,000) with a
diagnosis of rheumatoid arthritis were available, with a
large number (>6,000) of different ICD9 diagnostic
codes. Most prevalent co-morbidities were in the cardio-
vascular area: hypertension, chest pain and hyperlipide-
mia. The rank-ordering of relative risks shows a variety
of conditions to be associated with RA. Some of these
have been reported previously such as fibrosing alveolitis
[17,18] and acute stomach ulcer [19,20]; it also shows a
strong and statistically significant association with osteo-
myelitis. Published studies on even relatively large
cohorts of RA patients typically show only a few cases
of this rare but severe infection. [21-23]. Also, of note,
is the strong association found with ‘adverse effect to
medication’; this is an ICD-9 category with no informa-
tion on the nature of the reaction or the product
imputed. RR for osteoporosis is markedly increased, also
for various fractures; this is in line with the findings of
Van Staa et al based on the General Practice Research
Database in the UK [24]. Osteoporosis is likely a direct
consequence of RA, decreased physical activity and
treatments with corticosteroids [25]. The association of
RA with psoriatic arthropathy may be a consequence of
Table 2 Top 30 Relative risks of co-morbidities in patients with rheumatoid arthritis 16 years and older as compared
with control group (N = 61,591 for each group)
ICD9 Co-morbidity Condition Persons with RA (N) Percent RR 95% CI
6960 Psoriatic arthropathy 1,540 2.5% 12.3 10.5-15.1
99529 Adverse effect medicinal and biologic substance NEC/NOS 360 0.6% 7.7 5.7-10.4
99666 Reaction-internal joint prosthesis 131 0.2% 4.0 2.7-5.8
9952 Unspecified adverse effect drug, medicinal and biol substance properly administered 717 1.2% 3.9 3.4-4.7
73309 Osteoporosis NEC 479 0.8% 3.9 3.2-4.8
5163 Idiopathic fibrosing alveolitis 205 0.3% 3.9 2.9-5.2
73027 Osteomyelitis NOS-ankle 148 0.2% 3.5 2.5-5.0
2793 Immunity deficiency NOS 81 0.1% 3.4 2.1-5.3
7901 Elevated sediment rate 171 0.3% 3.3 2.4-4.5
7955 Tuberculin test reaction abnormal or positive 239 0.4% 3.3 2.5-4.3
99520 Adverse effect medicinal and biologic substance NOS 708 1.1% 3.2 2.8-3.8
73020 Osteomyelitis NOS-unspec 119 0.2% 3.1 2.2-4.5
28529 Anemia-of other chronic illness 415 0.7% 3.1 2.6-3.8
2550 Cushing’s syndrome 61 0.1% 3.0 1.8-5.1
515 Postinflammatory pulmonary fibrosis 1,221 2.0% 3.0 2.7-3.4
2841 Pancytopenia 80 0.1% 3.0 1.9-4.6
4920 Emphysematous BLEB 72 0.1% 2.9 1.8-4.5
79579 Other and unspecified nonspecific immunologic findings 373 0.6% 2.8 2.3-3.5
2794 Autoimmune disease NEC 142 0.2% 2.8 2.1-3.9
5369 Stomach function disorder NOS 67 0.1% 2.8 1.8-4.4
4430 Raynaud’s syndrome 251 0.4% 2.8 2.2-3.5
53130 Acute stomach ulcer NOS 76 0.1% 2.7 1.8-4.2
70709 Decubitus ulcer, site NEC 97 0.2% 2.7 1.8-4.0
8082 Fracture of pubis-closed 136 0.2% 2.7 1.9-3.7
27549 Disorders of calcium metabolism NEC 69 0.1% 2.6 1.7-4.2
73340 Aseptic necrosis bone NOS 75 0.1% 2.6 1.7-4.0
8088 Pelvic fracture NOS-closed 121 0.2% 2.6 1.8-3.6
73007 Acute osteomyelitis-ankle 77 0.1% 2.6 1.7-3.9
4476 Arteritis NOS 247 0.4% 2.5 2.0-3.2
73302 Idiopathic osteoporosis 182 0.3% 2.5 1.9-3.3
*Aged at least 16 years, matched controls with Dermatitis/Eczema diagnosis.
Only includes conditions for which there were at least 20 controls Excluded Arthritis/RA-related codes ICD 710-729;996.4.
NOS: Not otherwise specified NEC: Not elsewhere classified.
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stages where follow-up of patients would lead to a
change of diagnosis. Psoriatic arthropathy is in the ICD
category of skin conditions; hence it was included in
Table 2. The many diagnostic codes that are part of
ICD categories that cover arthritis and other conditions
of the locomotor system have been excluded as these
were not the focus of the co-morbidity analysis. How-
ever these are included in additional File 1: Rank-
ordered relative risks of co-morbidities in patients with
rheumatoid arthritis.
All RRs shown in Table 2 are statistically significant
with lower boundaries of the 95% confidence interval
above 1. This is a result of conditions being both
strongly associated with RA and not too rare (at least 20
cases in control group).
It should be stressed that some less common events
may be highly relevant from a drug safety perspective.
A data set covering information on patients with RA or
any other condition may indeed be used for analysis of
any event of interest, irrespective of its rate of
occurrence.
The control group included a group of patients with a
non-systemic chronic condition (eczema/dermatitis)
occurring in a broad age range, but with no direct rela-
tion to RA.
The choice of a control group of patients with another
chronic condition should help to control for bias in
detecting co-morbidities asb o t hg r o u p sh a v ee x p o s u r e
to health care. It should be noted however that some
diagnoses that are relatively common both in the gen-
eral population and in the RA population such as var-
ious skin conditions have a RR under 1 due to an
association with the control group. For example ‘pruritic
disorders NOS’ had a RR of 0.40.
Various control groups may be selected, depending on
the types of outcomes of interest. For example, some
diagnoses are typically made in the setting of out-patient
clinics, other ones during hospital stays. The choice of
control groups should take these differences into
account.
As with any data source, claims data have limitations
which are due both to the nature of administrative
claims for payment purposes and convenience samples
as opposed to random samples of the population. As
such, they may contain biases or fail to generalize well
to other populations. Clinical knowledge about comor-
bidities of RA or eczema/dermatitis is likely to drive the
conditions that clinicians test for and deem worth
recording. Information on important aspects such as
smoking behaviour and ethnicity is missing. Associations
found should not be considered to be causal. Rank-
Figure 2 Top 30 Relative risks of co-morbidities in patients with rheumatoid arthritis 16 years and older as compared with control
group (N = 61,591 for each group).
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identify characteristics specific to patients with a condi-
tion of interest. This can be applied to various sub-
groups of patients with the condition selected such as
patients treated with different pharmaceutical products
of interest. Comparisons of such groups can show
whether products are prescribed to patients with differ-
ent co-morbidity patterns prior to treatment. Under-
standing such selective prescribing can help in the
interpretation of reported adverse effects of new pro-
ducts, as a part of good risk management practice.
Conclusions
Rank-ordering of relative risks of diagnostic codes is a
tool to quickly identify co-morbidities specific to a
patient group of interest, in this case patients with rheu-
matoid arthritis. Conditions with a strong (RR > 3), sta-
tistically significant association with RA included
osteomyelitis; the large cohort of RA patients (> 60,000)
covered makes it possible to quantify risk for this and
other uncommon co-morbiditities.
Additional material
Additional file 1: Rank-ordered Relative Risks of co-morbidities in
patients with rheumatoid arthritis. RR as compared with control
group (N = 61,591 for each group). 16 years and older. Arthritis/RA-
related codes included. Conditions included for which there were at
least 20 controls. Number of RA cases in table may be less than 20 if RR
< 1, i.e. if fewer cases than controls have condition. Shown: ICD9 codes,
description of co-morbidity, number of persons in group with RA,
percentage of group with RA, Relative Risk. NOS: Not otherwise specified
NEC: Not elsewhere classified.
Additional file 2: Top 30 Relative risks and Odds ratios in patients
with rheumatoid arthritis. Comparator group with Dermatitis/
Eczema diagnosis (N = 61,591 for each group). 16 years and older.
RR + OR with 95% confidence intervals. Conditions included for
which there were at least 20 controls. Shown: ICD9 codes, description of
co-morbidity, numbers of persons with co-morbidity in RA and control
groups, Relative Risk, numbers of persons without co-morbidity in RA
and control groups, Odds Ratio. 95% Confidence Intervals.
Additional file 3: Top 30 Relative risks and Odds ratios in patients
with rheumatoid arthritis. Comparator random group (N = 61,591
for each group). 16 years and older RR + OR with 95% confidence
intervals. Conditions included for which there were at least 20 controls.
Shown: ICD9 codes, description of co-morbidity, numbers of persons
with co-morbidity in RA and control groups, Relative Risk, numbers of
persons without co-morbidity in RA and control groups, Odds Ratio. 95%
Confidence Intervals.
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